Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSV-Tk–transduced donor lymphocyte infusion after T-cell–depleted allogeneic stem cell transplantation in leukemia
DRKS00000211Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2010
- Countries
- 1
- Sponsor
- Medizinische Hochschule Hannover
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Drugs
- ganciclovir
- Conditions
- chronic myelogenous leukemia (CML)Acute Leukaemia
01
Overview
Phase 2, open-label, single-arm trial of ganciclovir in chronic myelogenous leukemia (CML) and Acute Leukaemia, sponsored by Medizinische Hochschule Hannover. Started Jan 2010; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
HSV-Tk–transduced donor lymphocyte infusion + conditional ganciclovir after T-cell–depleted allogeneic SCT
Single-arm cohort receiving standard myeloablative conditioning with total body irradiation and cyclophosphamide followed by T-cell–depleted allogeneic stem cell transplantation, then HSV-Tk–transduced donor lymphocyte infusion; ganciclovir is started only if patients develop grade II–IV…
03
Who it enrols
Patients with chronic myeloid leukemia or acute leukemia in complete remission following T-cell–depleted allogeneic stem cell transplantation, candidates for donor lymphocyte infusion with HSV-Tk–transduced allogeneic lymphocytes and potential ganciclovir treatment in case of grade II–IV graft-versus-host disease.
Beyond the preview
Go deeper on DRKS00000211.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000211.